NO974610L - Trisykliske forbindelser som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer - Google Patents

Trisykliske forbindelser som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer

Info

Publication number
NO974610L
NO974610L NO974610A NO974610A NO974610L NO 974610 L NO974610 L NO 974610L NO 974610 A NO974610 A NO 974610A NO 974610 A NO974610 A NO 974610A NO 974610 L NO974610 L NO 974610L
Authority
NO
Norway
Prior art keywords
inhibition
treatment
compounds useful
proliferative diseases
protein function
Prior art date
Application number
NO974610A
Other languages
English (en)
Other versions
NO974610D0 (no
NO314082B1 (no
Inventor
Adriano Afonso
John J Baldwin
Ronald James Doll
Ge Li
Alan K Mallams
F George Njoroge
Dinanath F Rane
John C Reader
Randall R Rossman
Original Assignee
Schering Corp
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp
Publication of NO974610D0 publication Critical patent/NO974610D0/no
Publication of NO974610L publication Critical patent/NO974610L/no
Publication of NO314082B1 publication Critical patent/NO314082B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19974610A 1995-04-07 1997-10-06 Trisykliske forbindelser som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer NO314082B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41832395A 1995-04-07 1995-04-07
PCT/US1996/004172 WO1996031478A1 (en) 1995-04-07 1996-04-03 Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
NO974610D0 NO974610D0 (no) 1997-10-06
NO974610L true NO974610L (no) 1997-12-08
NO314082B1 NO314082B1 (no) 2003-01-27

Family

ID=23657636

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974610A NO314082B1 (no) 1995-04-07 1997-10-06 Trisykliske forbindelser som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer

Country Status (20)

Country Link
EP (1) EP0819121B1 (no)
JP (1) JP3038017B2 (no)
KR (1) KR100329877B1 (no)
AR (1) AR003116A1 (no)
AT (1) ATE363472T1 (no)
AU (1) AU719990B2 (no)
BR (1) BR9604787A (no)
CA (1) CA2217499C (no)
CZ (1) CZ316597A3 (no)
DE (1) DE69637105T2 (no)
ES (1) ES2288302T3 (no)
HU (1) HUP9800456A3 (no)
IL (1) IL117798A (no)
MX (1) MX9707665A (no)
NO (1) NO314082B1 (no)
NZ (1) NZ306665A (no)
PL (1) PL322689A1 (no)
SK (1) SK135597A3 (no)
TW (1) TW462968B (no)
WO (1) WO1996031478A1 (no)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CN1326847C (zh) * 1995-12-22 2007-07-18 先灵公司 三环酰胺类用于抑制g－蛋白功能及治疗增生疾病
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5767274A (en) * 1996-06-28 1998-06-16 Biomeasure, Incorporated Prenyl transferase inhibitors
US5925757A (en) * 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
BR9712035A (pt) * 1996-09-13 1999-08-24 Schering Corp Compostos Úteis para inibi-Æo de transferase de prote¡na farnesila
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
EP0927181A1 (en) * 1996-09-13 1999-07-07 Schering Corporation Tricyclic compounds useful as fpt inhibitors
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
KR20000036111A (ko) * 1996-09-13 2000-06-26 둘락 노먼 씨. 파네실 단백질 트랜스페라제 억제제인 트리사이클릭 항종양성화합물
US6030982A (en) * 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
CA2266014A1 (en) * 1996-09-13 1998-03-19 Schering Corporation Tricyclic compounds useful for inhibition of farnesyl protein transferase
CN1104427C (zh) * 1996-09-13 2003-04-02 先灵公司 法呢基蛋白转移酶的三环抑制剂
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
AU6441498A (en) * 1997-03-25 1998-10-20 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US5998620A (en) * 1997-03-25 1999-12-07 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
HUP0004627A2 (hu) * 1997-06-17 2001-10-28 Schering Corp. Farnezil-protein transzferáz inhibitor hatású új triciklusos szulfonamidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
US6358968B1 (en) 1997-06-17 2002-03-19 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
EP0989983B1 (en) * 1997-06-17 2004-08-11 Schering Corporation Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
US6426352B1 (en) 1997-06-17 2002-07-30 Schering Corporation Sulfonamide inhibitors of farnesyl-protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
AU7815198A (en) * 1997-06-17 1999-01-04 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
WO1998057964A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
AU8253598A (en) * 1997-06-17 1999-01-04 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6410534B1 (en) 1998-07-02 2002-06-25 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000001382A1 (en) 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6307048B1 (en) 1998-11-20 2001-10-23 Schering Corporation Enantioselective alkylation of tricyclic compounds
WO2000030589A2 (en) * 1998-11-20 2000-06-02 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6372909B1 (en) 1998-11-20 2002-04-16 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6800636B2 (en) 1998-12-18 2004-10-05 Schering Corporation Farnesyl protein transferase inhibitors
PL348294A1 (en) * 1998-12-18 2002-05-20 Schering Corp Farnesyl protein transferase inhibitors
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
BR9916314A (pt) 1998-12-18 2001-10-02 Schering Corp Inibidores tricìclicos da proteìna farnesil transferase
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
AU2001288972A1 (en) * 2000-09-11 2002-03-26 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
CN1244562C (zh) 2001-08-21 2006-03-08 先灵公司 三环酮中间体的合成方法
US7189757B2 (en) 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
AU2002347906A2 (en) 2001-10-16 2003-04-28 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
JP4713152B2 (ja) * 2002-09-20 2011-06-29 メルク セローノ ソシエテ アノニム ピペラジン誘導体及び使用方法
US20060100435A1 (en) * 2002-09-24 2006-05-11 Sanjay Suri Process for the production of desloratadine
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
EP1656156A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
US7482460B2 (en) 2003-12-10 2009-01-27 Hypnion, Inc. Doxepin analogs and methods of use thereof
US7326721B2 (en) 2003-12-10 2008-02-05 Hypnion, Inc. Doxepin analogs and methods of use thereof
US7411069B2 (en) 2003-12-10 2008-08-12 Hypnion, Inc. Doxepin analogs and methods of use thereof
US7524864B2 (en) 2004-04-23 2009-04-28 Hypnion, Inc. Methods of treating sleep disorders
US7585864B2 (en) 2004-12-13 2009-09-08 Schering Corporation Farnesyl protein transferase inhibitors and their use to treat cancer
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2498043T3 (es) * 2006-06-06 2014-09-24 Cornerstone Therapeutics Inc. Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas
US7943622B2 (en) 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
DK2041088T3 (da) 2006-06-28 2014-04-07 Amgen Inc Glycintransporter-1 inhibitorer
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
CN101641350B (zh) * 2007-03-15 2012-11-28 ARYx医疗有限公司 二苯并[b,f][1,4]氧杂氮杂*化合物
KR20100017866A (ko) 2007-05-21 2010-02-16 노파르티스 아게 Ｃｓｆ－１ｒ 억제제, 조성물 및 사용 방법
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP2013522292A (ja) 2010-03-16 2013-06-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド インダゾール化合物およびそれらの使用
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
DE68916699T2 (de) * 1988-04-28 1994-12-01 Schering Corp Benzopyridopiperidin, -piperidyliden und -piperazin-Verbindungen, Zusammensetzungen, Methoden zur Herstellung und Verwendung.
ZA914764B (en) * 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
WO1992006970A1 (en) * 1990-10-10 1992-04-30 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JPH0676403B2 (ja) * 1991-01-18 1994-09-28 エスエス製薬株式会社 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤
JP2974529B2 (ja) * 1992-02-20 1999-11-10 北陸製薬株式会社 両性型三環系化合物
WO1995010515A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
SG43768A1 (en) * 1993-10-15 1997-11-14 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative dieases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them

Also Published As

Publication number Publication date
AR003116A1 (es) 1998-07-08
ATE363472T1 (de) 2007-06-15
DE69637105T2 (de) 2008-04-24
NO974610D0 (no) 1997-10-06
IL117798A0 (en) 1996-08-04
PL322689A1 (en) 1998-02-16
ES2288302T3 (es) 2008-01-01
AU719990B2 (en) 2000-05-18
HUP9800456A3 (en) 2000-04-28
BR9604787A (pt) 1998-07-07
NZ306665A (en) 2000-01-28
JPH10511981A (ja) 1998-11-17
AU5527996A (en) 1996-10-23
HUP9800456A2 (hu) 1999-06-28
SK135597A3 (en) 1998-07-08
TW462968B (en) 2001-11-11
EP0819121B1 (en) 2007-05-30
CZ316597A3 (cs) 1998-03-18
EP0819121A1 (en) 1998-01-21
CA2217499C (en) 2004-03-30
WO1996031478A1 (en) 1996-10-10
NO314082B1 (no) 2003-01-27
MX9707665A (es) 1997-11-29
JP3038017B2 (ja) 2000-05-08
CA2217499A1 (en) 1996-10-10
DE69637105D1 (de) 2007-07-12
KR100329877B1 (ko) 2002-08-28
IL117798A (en) 2001-11-25

Similar Documents

Publication Publication Date Title
NO974610L (no) Trisykliske forbindelser som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
NO982878D0 (no) Trisykliske amider som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
IL117603A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
DE69626104D1 (de) Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und zur behandlung von proliferativen erkrankungen
AU6594796A (en) Photoactivatable compounds for the prevention of intimal hyperplasia and other diseases
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
NO961006L (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69612465D1 (de) Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
FI954119A0 (fi) Menetelmä kiinteän jätteen käsittelemiseksi
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
NO20003229L (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske midler for behandling av proliferaktive sykdommer
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
EE9700168A (et) Teraapias kasutatavad bitsüklilised isotiokarbamiidi derivaadid
IL117797A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
NO944931D0 (no) Anvendelse av 2-fenyl-3-arroylbenzotiofener for inhibering av tidlig seksuell modenhet
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
NO981822D0 (no) Anvendelse av proteinet GAX for behandling av cancer
EE03437B1 (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO982562D0 (no) Sammensetning for behandling av smerte
NO993549L (no) Imino-aza-antracyklinonderivater til behandling av amyloidosis
NO953089D0 (no) Steroider for behandling av menopausale plager

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees